2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.20 (Poster) Hospitalization patterns for immune-related adverse events in patients with NSCLC treated with immunotherapy vs chemo-immunotherapy

PP01.20 (Poster) Hospitalization patterns for immune-related adverse events in patients with NSCLC treated with immunotherapy vs chemo-immunotherapy

Back to course

Pdf Summary

A retrospective study was conducted to evaluate hospitalization patterns for immune-related adverse events (irAEs) in patients with stage IV non-small cell lung cancer (NSCLC) treated with pembrolizumab immunotherapy, either alone or in combination with chemotherapy. The study included 312 patients treated at the Ohio State University Comprehensive Cancer Center from 2018 to 2022. <br /><br />The study found that a significant proportion of metastatic NSCLC patients treated with pembrolizumab were hospitalized for various reasons within one year of starting treatment. The hospitalizations due to irAEs were more likely to occur within the first six months following the start of immunotherapy. <br /><br />The types of irAEs leading to hospitalization varied among the patients, but specific details were not provided. However, there were no differences in hospitalization rates between patients treated with pembrolizumab alone and those treated with pembrolizumab in combination with chemotherapy. <br /><br />The demographic characteristics of the patients included a majority of white patients (85.6%), with a mean age of 64.1 years. Most patients were male (55.8%) and had positive PD-L1 expression (64.7%). The most common NSCLC histology was adenocarcinoma (67.0%). <br /><br />The study highlights the importance of monitoring and managing irAEs in patients receiving immunotherapy for NSCLC. The findings suggest that early recognition and intervention for irAEs may help reduce hospitalizations and improve patient outcomes. <br /><br />Further research is needed to better understand the specific irAEs leading to hospitalization and to develop strategies for preventing and managing these adverse events in NSCLC patients receiving immunotherapy. <br /><br />The study was supported by the National Center for Advancing Translational Sciences. <br /><br />References: <br /><br />1. Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint <br />Blockade Therapy. Cancer Discov. 2018;8(9):1069-1086. <br /><br />2. Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL. Immune-Related <br />Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Curr Oncol <br />Rep. 2020;22(4):39.

Asset Subtitle

Adam Khorasanchi

Keywords

retrospective study

hospitalization patterns

immune-related adverse events

stage IV non-small cell lung cancer

pembrolizumab immunotherapy

chemotherapy

metastatic NSCLC

irAEs

monitoring

managing irAEs